Saturday 20 April 2019 ,
Saturday 20 April 2019 ,
Latest News
  • AL govt’s popularity increases: PM
  • Nusrat murder: Sonagazi AL chief Ruhul Amin held
  • Send Subir Nandi’s medical docs to Singapore for expert opinions: PM
  • Rohingyas must go back: PM
  • Motive behind Nusrat murder evident: Minister
11 February, 2019 00:00 00 AM

FDA approves Tosymra (sumatriptan) nasal spray for acute treatment of migraine

drugs.com
FDA approves Tosymra (sumatriptan) nasal spray for acute treatment of migraine

Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC recently announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment portfolio. The company is working toward commercialization of this product.

“We are excited about the approval of Tosymra. This approval affirms our ability to develop well-differentiated products to meet the unmet needs of patients with migraine and HCPs treating them,” said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories.

According to Dr. Anil Namboodiripad, PhD, President, Promius Pharma, “Tosymra nasal spray is formulated using a proprietary novel excipient known as Intravail [®] to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action. Independent research shows that 26% to 40% of migraine patients are not optimally controlled with their current treatment.

[1] For patients who suffer from the debilitating and disruptive effects of migraine, there continues to be a need for reliable and efficacious treatment options. At Promius, we are committed to developing new ways of improving patient experiences. Tosymra is a mist-like nasal spray that acts rapidly and is well tolerated.”

Important patient safety information

Tosymra can cause serious side effects, including: heart attack and other heart problems, which may lead to death.

Stop using Tosymra and get emergency medical help right away if you have any of the following symptoms of a heart attack:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back

severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw

pain or discomfort in your arms, back, neck, jaw, or stomach

shortness of breath with or without chest discomfort

breaking out in a cold sweat

nausea or vomiting

feeling lightheaded

Tosymra is not for people with risk factors for heart disease (high blood pressure, high cholesterol levels, smoking, overweight, diabetes, family history of heart disease) unless a heart exam is done and shows no problem.

Do not use Tosymra if you have:

heart problems or a history of heart problems

narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)

uncontrolled high blood pressure

severe liver problems

hemiplegic migraines or basilar migraines. If you are not sure if you have these, ask your healthcare provider

had a stroke, transient ischemic attacks (TIAs), or problems with your blood circulation

taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your healthcare provider if you are not sure if your medicine is listed above

are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.

an allergy to sumatriptan or any of the ingredients in Tosymra.

What are possible side effects of Tosymra?

Tosymra may cause serious side effects including:

changes in color or sensation in your fingers and toes (Raynaud’s syndrome)

stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include: sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever

problems with blood circulation to your legs and feet (peripheral vascular ischemia). Symptoms of peripheral vascular ischemia include: cramping and pain in your legs or hips, feeling of heaviness or tightness in your leg muscles, burning or aching pain in your feet or toes while resting, numbness, tingling, or weakness in your legs, cold feeling or color changes in 1 or both legs or feet

Increased blood pressure including a sudden severe increase (hypertensive crisis) even if you have no history of high blood pressure

medication overuse headaches. Some people who use too much migraine medicine, such as Tosymra, for 10 or more days each month may have worse headaches (medication overuse headache).

If your headaches get worse, your healthcare provider may decide to stop your treatment with Tosymra.

serotonin syndrome. Serotonin syndrome is a rare but serious problem that can happen in people using Tosymra, especially if Tosymra is used with anti-depressant medicines called SSRIs or SNRIs.

Call your healthcare provider right away if you have any of the following:

symptoms of serotonin syndrome: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking

hives (itchy bumps); swelling of your tongue, mouth, or throat

seizures have happened in people taking sumatriptan who have never had seizures before

The most common side effects of Tosymra include tingling, dizziness, feeling warm or hot, burning feeling, feeling of heaviness, feeling of pressure, flushing, feeling of tightness, numbness, application site (nasal) reactions, abnormal taste, and throat irritation.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Tosymra. For more information, ask your healthcare provider or pharmacist.

What is Tosymra used for?

Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.

Tosymra is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines. Tosymra is not used to treat cluster headaches.

Tosymra is not used to prevent or decrease the number of migraines you have.

It is not known if Tosymra is safe and effective in children under 18 years of age.

 

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Haemophilia, a bleeding disorder, is our cover story this week. Haemophilia is caused by a deficiency in one of the blood clotting factors. Haemophilia…
Haemophilia and World Haemophilia Day

Haemophilia and World Haemophilia Day

World Haemophilia Day is an international awareness day for haemophilia and other bleeding disorders. It is held annually on April 17, date of the birthday…
Haemophilia A: Genetic testing and what to expect

Haemophilia A: Genetic testing and what to expect

LANA BARHUM   Genetic testing for Hemophilia A is widely available and includes carrier testing, direct DNA mutation testing, linkage testing, and…
Blood disorders and its affects

Blood disorders and its affects

Blood disorders can affect any of the three main components of blood: Red blood cells, which carry oxygen to the body's tissues White blood cells,…
Bleeding tendencies in children

Bleeding tendencies in children

Rahim, a 3 year old boy hailing from Manikgonj presented in Paediatric OPD of Dhaka Shishu Hospital with his mother who complained that Rahim had fine…
10 facts on blood transfusion

10 facts on blood transfusion

Blood transfusion saves lives and improves health, but many patients requiring transfusion do not have timely access to safe blood. The need for blood…
Bruises and its treatments

Bruises and its treatments

A bruise is a common skin injury that results in a discoloration of the skin. Blood from damaged blood cells deep beneath the skin collects near the surface…
A tiny cry for help from inside the liver could lead to better treatment

A tiny cry for help from inside the liver could lead to better treatment

On a normal day, the cells of a human liver do what they do best—making key blood proteins, clearing toxins from the blood and sending their remains…
Food better than supplements for longevity

Food better than supplements for longevity

 TRISHA CALVO A new Tufts University study involving more than 27,000 Americans is the latest research to show that most supplements may not do much…
icddr,b and partners explore pathways of antibiotic use in Bangladesh and ways to intervene

icddr,b and partners explore pathways of antibiotic use in Bangladesh and ways to intervene

Recently, scientists at icddr,b in collaboration with Loughborough University, Durham University and the University of Bristol, UK have organised a dissemination…
Recurrence score may cut costs for high-risk breast cancer care

Recurrence score may cut costs for high-risk breast cancer care

Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients…
Call to ensure universal health coverage

Call to ensure universal health coverage

Health experts called for taking necessary steps for ensuring universal health coverage across the country in the greater interest of the country. A huge…
FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

FDA approves Dovato (dolutegravir/lamivudine) for HIV-1 infection

ViiV Healthcare recently announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting